MARKET

XBIT

XBIT

XBiotech
NASDAQ

Real-time Quotes | Nasdaq Last Sale

16.66
-0.31
-1.83%
Pre Market: 16.66 0 0.00% 08:51 05/06 EDT
OPEN
17.00
PREV CLOSE
16.97
HIGH
17.07
LOW
16.56
VOLUME
31
TURNOVER
--
52 WEEK HIGH
21.48
52 WEEK LOW
12.76
MARKET CAP
499.51M
P/E (TTM)
-43.0046
1D
5D
1M
3M
1Y
5Y
Das French National Cancer Institute und XBiotech kooperieren bei einer innovativen, adaptiven, multizentrischen klinischen Studie der Phase II/III zum neuen Arzneimittel von XBiotech gegen das kolorektale Karzinom
XBiotech liefert INSERM sein neues Medikament zur Verwendung als Kombinationstherapie fur die Behandlung eines fortgeschrittenen kolorektalen Karzinoms
Globe Newswire · 1d ago
French National Cancer Institute and XBiotech Join forces to Conduct Innovative Phase II/III Adaptive Multicenter Clinical Study for XBiotechs New Cancer Drug for Colorectal Cancer
GlobeNewswire · 3d ago
XBiotech To Test New Drug Candidate Combined With Approved Treatment In Pancreatic Cancer
Benzinga · 04/19 11:08
Peloton, Coca-Cola, Tesla: What to Watch When the Stock Market Opens Today
Another batch of earnings reports from major corporations are due.
marketwatch.com · 04/19 10:55
DJ XBiotech Gets FDA OK for Phase I/II Study of XB2001 in Pancreatic Cancer
Dow Jones · 04/19 10:30
FDA Granted Permission for XBiotech's Candidate Therapy for Phase I/II Double-blind Placebo Controlled Study in Pancreatic Cancer
XBiotech (NASDAQ: XBIT) announced today that the FDA has granted permission to commence clinical trials with its novel drug candidate for treating patients with pancreatic cancer. From 1992 to 2018 the death rate from pancreatic cancer steadily increased i...
Benzinga · 04/19 09:32
FDA gives go-ahead for XBiotech’s XB2001 combo therapy in pancreatic cancer
XBiotech (XBIT) announces that the FDA has granted permission to commence clinical trials with its novel drug candidate for treating patients with pancreatic cancer. The Phase I/II clinical study will evaluate XBiotech’s
Seekingalpha · 04/19 08:27
BRIEF-Xbiotech Says FDA Has Granted Permission To Commence Clinical Trials With Its Novel Drug Candidate For Treating Patients With Pancreatic Cancer
reuters.com · 04/19 08:12
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of XBIT. Analyze the recent business situations of XBiotech through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average XBIT stock price target is 18.00 with a high estimate of 18.00 and a low estimate of 18.00.
EPS
Institutional Holdings
Institutions: 90
Institutional Holdings: 4.02M
% Owned: 13.39%
Shares Outstanding: 29.98M
TypeInstitutionsShares
Increased
18
115.62K
New
7
169.87K
Decreased
22
173.19K
Sold Out
8
60.88K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.92%
Pharmaceuticals & Medical Research
+0.20%
Key Executives
Chairman/President/Chief Executive Officer/Founder/Director
John Simard
Chief Scientific Officer
Sushma Shivaswamy
Chief Financial Officer
Scott Whitehurst
Vice President - Finance/Director of Human Resources/Secretary
Queena Han
Lead Director/Independent Director
Jan-Paul Waldin
Independent Director
Peter Libby
Independent Director
Donald MacAdam
Independent Director
W. Thorpe McKenzie
No Data
About XBIT
XBiotech Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. It focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response. The Company has also developed a True Human monoclonal antibody discovery platform and manufacturing system. Xilonix is a therapeutic antibody, which specifically neutralizes interleukin-1 alpha (IL-1a). Its pipeline includes various human antibodies for treating diseases, such as cancer, vascular disease, inflammatory skin disease and diabetes. The Company has completed a Phase III study in Europe for the treatment of symptomatic colorectal cancer. It also investigated its lead product candidate in clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS).

Webull offers kinds of XBiotech Inc stock information, including NASDAQ:XBIT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XBIT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XBIT stock methods without spending real money on the virtual paper trading platform.